Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.